Lyell Immunopharma (NASDAQ:LYEL) Coverage Initiated at Stifel Nicolaus

Equities researchers at Stifel Nicolaus started coverage on shares of Lyell Immunopharma (NASDAQ:LYEL) in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $36.00 price target on the stock. Stifel Nicolaus’ price target indicates a potential upside of 144.73% from the stock’s current price.

Several other equities research analysts have also commented on LYEL. Citizens Jmp reiterated a “market outperform” rating and set a $34.00 price target on shares of Lyell Immunopharma in a research note on Monday, June 15th. Wall Street Zen upgraded shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price objective on shares of Lyell Immunopharma in a report on Monday, June 15th. B. Riley Financial assumed coverage on Lyell Immunopharma in a research report on Wednesday, July 22nd. They set a “buy” rating and a $44.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 9th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Lyell Immunopharma currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Lyell Immunopharma Stock Performance

NASDAQ LYEL opened at $14.71 on Thursday. The firm has a market cap of $360.39 million, a price-to-earnings ratio of -1.15 and a beta of -0.04. The firm has a 50 day simple moving average of $13.44 and a 200-day simple moving average of $19.01. Lyell Immunopharma has a one year low of $9.28 and a one year high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.92) earnings per share for the quarter, topping the consensus estimate of ($2.02) by $0.10. Lyell Immunopharma had a negative return on equity of 87.60% and a negative net margin of 920,285.25%.The company had revenue of $0.00 million for the quarter, compared to the consensus estimate of $0.01 million. Equities analysts predict that Lyell Immunopharma will post -7.69 EPS for the current fiscal year.

Institutional Trading of Lyell Immunopharma

Institutional investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in shares of Lyell Immunopharma in the 2nd quarter worth about $347,000. Bank of America Corp DE increased its holdings in Lyell Immunopharma by 314.2% during the 1st quarter. Bank of America Corp DE now owns 33,321 shares of the company’s stock valued at $668,000 after acquiring an additional 25,276 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Lyell Immunopharma by 194.8% during the 1st quarter. Renaissance Technologies LLC now owns 116,411 shares of the company’s stock valued at $2,335,000 after acquiring an additional 76,921 shares in the last quarter. Walleye Capital LLC acquired a new position in Lyell Immunopharma during the first quarter worth about $445,000. Finally, Dimensional Fund Advisors LP acquired a new position in Lyell Immunopharma during the first quarter worth about $959,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

Lyell Immunopharma Company Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.